Hologic Acquires Interlace Medical

Interlace's operations will be integrated within Hologic's gynecological surgical products division, and Hologic will also roll out physician training and education programs for the MyoSure hysteroscopic tissue removal system, culminating in the full integration and promotion of the product in early 2011. The purchase price for the transaction was US$125 million in cash, subject to adjustment, plus two annual contingent payments, which will be calculated as a multiple of the incremental revenue growth over the prior year, payable in cash.

"MyoSure is an innovative technology that is designed to safely and easily remove fibroids and polyps that plague millions of women. This product is a natural extension of our industry-leading OB/GYN product portfolio which now provides women with minimally invasive treatment options - from their child bearing years to menopause,” said Steve Williamson, senior vice president and general manager of gynecological surgical products at Hologic. "The strong clinical performance and ease of use of the MyoSure device make it a natural fit with our NovaSure endometrial ablation and Adiana permanent contraception product lines.”

"We are excited to be joining Hologic to build upon the early success of MyoSure,” said Bill Gruber, president and CEO of Interlace. "Hologic has established itself as the leader in women's health with best-in-class products, medical education, and physician training, service, and support capabilities. By joining forces, we are confident we can give more women in need access to the MyoSure treatment.”

The MyoSure hysteroscopic tissue-removal system is a new treatment that is designed to provide incision-less, fast, and safe removal of intracavitary fibroids and polyps, and effective relief of the associated abnormal uterine bleeding symptoms. The system provides a treatment option for women seeking to preserve uterine form and function while providing gynecologists with a minimally invasive care option for their patients. Clinical studies have shown the efficacy rate for hysteroscopic removal of fibroids is very high, with close to 96% of patients receiving symptom resolution and a recurrence at five years of less than 10%.

Related Links:
Hologic
Interlace Medical